GSK plc (LSE/NYSE: GSK) today announced positive phase III data from its clinical programme to develop a next-generation version of its metered dose inhaler (MDI), Ventolin (salbutamol). Data confirm that the formulation of salbutamol MDI…
GSK announces positive pivotal phase III data for next-generation low carbon version of Ventolin (salbutamol) metered dose inhaler
